Big Pharma must lose its resistance to antibiotic research and more

Anjana AhujaAnjana Ahuja

Profit cannot be sole motive of an industry founded on making people better, writes Anjana Ahuja
©Dreamstime

The sun has started shining at exactly the wrong time. When the weather warms, memories of winter recede. We forget not only the biting temperatures but also the ailments that follow: influenza, infections and, for the unluckiest, pneumonia. And we forget that antibiotics have enabled the most vulnerable to live to enjoy another British spring.

That could be why the economist (and new government minister) Jim O’Neill’s latest report on antimicrobial resistance, published as part of an ongoing government-commissioned review, did not attract the publicity it deserved. With drug resistance a global threat that could cost 10m lives annually by 2050, this paper focused on how pharmaceutical companies could make a return from developing new medicines to tackle drug-resistant bacteria. Read More

Grapevine: Pharma firms seeking space

A recent blockbuster deal between GlaxoSmithKline and Novartis could mean a move or two in New Jersey’s commercial real estate market.

The two pharmaceutical giants in March completed a three-part deal that saw Novartis acquire GSK’s oncology portfolio, GSK acquire Novartis’ vaccine business and the creation of a joint venture consumer health care unit. As a result, a source said, the combined entity has been in the hunt for about 150,000 square feet in Somerset County. Read More

Exosome Diagnostics Announces Positive Results from Large Clinical Validation Study of Prostate Cancer Liquid Biopsy

Novel urine-based test demonstrates ability to accurately predict high-grade prostate cancer; holds potential to advance new prognostic paradigm, reduce unnecessary tissue biopsies

Outcomes and Economic Studies Planned in 2015, Commercial Launch Planned in 2016

NEW ORLEANS, La., and CAMBRIDGE, Mass.–(BUSINESS WIRE)–Exosome Diagnostics, Inc., a developer of revolutionary, biofluid-based molecular diagnostics, today announced positive data from a large clinical validation study of its novel prostate cancer liquid biopsy test. The study met its primary endpoint demonstrating that the urine-based liquid biopsy test when added to the current prognostic standard of care (SOC) significantly improved the ability to accurately predict high-grade prostate cancer in men presenting for an initial biopsy. James McKiernan, M.D., John K. Lattimer Professor and Chair, Department of Urology at New York-Presbyterian Hospital/Columbia University Medical Center and principal investigator of the study, presented the data today in a late-breaking plenary session at the American Urological Association (AUA) Annual Meeting in New Orleans, La. Read More

One in 10 kids receive attention-deficit/hyperactivity disorder diagnosis

HealthDay News — One in 10 children and teens have been diagnosed with attention-deficit/hyperactivity disorder, and that number has remained constant since 2007, according to government estimates.

To estimate how many children, aged 4 to 17 years, have received a diagnosis of attention-deficit/hyperactivity disorder (ADHD), Patricia N. Pastor, PhD, of the CDC’s National Center for Health Statistics, and colleagues combined results from the 2011, 2012, and 2013 National Health Interview Surveys. Read More

Get Med Career News in your Inbox!

If you want to keep up with the latest news and career tips in the Medical Field subscribe today!

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.